MX2007005368A - Formulacion con liberacion prolongada de dosis alta de gepirona. - Google Patents

Formulacion con liberacion prolongada de dosis alta de gepirona.

Info

Publication number
MX2007005368A
MX2007005368A MX2007005368A MX2007005368A MX2007005368A MX 2007005368 A MX2007005368 A MX 2007005368A MX 2007005368 A MX2007005368 A MX 2007005368A MX 2007005368 A MX2007005368 A MX 2007005368A MX 2007005368 A MX2007005368 A MX 2007005368A
Authority
MX
Mexico
Prior art keywords
further characterized
composition
weight
tablet
gepirone
Prior art date
Application number
MX2007005368A
Other languages
English (en)
Spanish (es)
Inventor
Stephen J Kramer
Louis F Fabre
Original Assignee
Fabre Kramer Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Holdings Inc filed Critical Fabre Kramer Holdings Inc
Publication of MX2007005368A publication Critical patent/MX2007005368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007005368A 2004-11-05 2004-11-05 Formulacion con liberacion prolongada de dosis alta de gepirona. MX2007005368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (1)

Publication Number Publication Date
MX2007005368A true MX2007005368A (es) 2007-09-11

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005368A MX2007005368A (es) 2004-11-05 2004-11-05 Formulacion con liberacion prolongada de dosis alta de gepirona.

Country Status (11)

Country Link
EP (1) EP1809255A4 (zh)
JP (1) JP2008519071A (zh)
CN (1) CN101076320A (zh)
AU (1) AU2004324868B2 (zh)
BR (1) BRPI0419179A (zh)
CA (1) CA2585606A1 (zh)
EA (1) EA013213B1 (zh)
IL (1) IL182792A0 (zh)
MX (1) MX2007005368A (zh)
NO (1) NO20072851L (zh)
WO (1) WO2006052227A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (it) * 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
RU2713725C1 (ru) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Биологически активная добавка и способ ее применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
JP2004517083A (ja) * 2000-12-08 2004-06-10 アクゾ・ノベル・エヌ・ベー ジェピロンの経口用持続放出性製剤
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Also Published As

Publication number Publication date
WO2006052227A1 (en) 2006-05-18
BRPI0419179A (pt) 2007-12-18
IL182792A0 (en) 2007-08-19
AU2004324868A1 (en) 2006-05-18
EP1809255A4 (en) 2011-08-03
EA200701010A1 (ru) 2007-10-26
AU2004324868B2 (en) 2010-04-29
EP1809255A1 (en) 2007-07-25
EA013213B1 (ru) 2010-04-30
CA2585606A1 (en) 2006-05-18
NO20072851L (no) 2007-07-31
JP2008519071A (ja) 2008-06-05
CN101076320A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
CA2157323C (en) Gepirone dosage form
US20090186084A1 (en) Form of administration of racecadotril
EP4082534A1 (en) Solid preparation, and preparation method therefor and use thereof
US20210353559A1 (en) Composition and method for treating neurological disease
US20200129454A1 (en) Composition and method for treating neurological disease
US11833121B2 (en) Composition and method for treating neurological disease
WO2006123213A1 (en) Modified release formulations of gliclazide
MX2007005368A (es) Formulacion con liberacion prolongada de dosis alta de gepirona.
US10328076B2 (en) Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof
US20060099267A1 (en) High-dosage extended-release formulation of gepirone
KR20070093972A (ko) 게피론의 고용량 서방성 제제
NZ554916A (en) High-dosage extended-release formulation of gepirone
RU2810927C2 (ru) Фармацевтические композиции с ингибитором cdc7
US20040204482A1 (en) Extended release oral dosage form
Njoroge Formulation and Evaluation of Oro-Dispersible Paediatric Sildenafil Tablets Using Jute Plant Mucilage
TWI600425B (zh) 環苄普林之延釋劑型
US20060222713A1 (en) Extended release pharmaceutical composition of phenytoin sodium
US20130150375A1 (en) GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
AU2002327991A1 (en) A new extended release oral dosage form

Legal Events

Date Code Title Description
FA Abandonment or withdrawal